Farnesyl transferase inhibitors (FTIs)
1 revert the anchorageindependent growth of several diverse tumors with and without ras mutations (2, 3) . 2 The compounds have limited effects on the growth of normal cells and are now being actively pursued for anti-cancer therapy (4 -9) . Although FTIs effectively suppress the anchorage-independent growth of hTCLs with Ha-ras mutations, hTCLs with K-ras or N-ras mutations show a variable response (2, 3, 10 -13) . This can be explained partially because FTIs are unable to prevent the membrane association of K-Ras or N-Ras. These two Ras isoforms are alternatively prenylated by the enzyme geranylgeranyl protein transferase (GGPT-I) in the presence of FTIs (14 -18) . Thus, the antitumor effects of FTIs in sensitive hTCLs with K-ras or N-ras mutations may be independent of effects on K-ras or N-ras function.
A critical hint to additional biological effects of FTIs was obtained from cell cycle studies showing that most cell lines that are sensitive to FTI treatment accumulate in the G 2 3 M phase of the cell cycle. 2 A protein that is farnesylated and contributes to cell cycle progression would be an appropriate candidate for mediating this biological effect. Since all farnesylated proteins end in a CAAX sequence (where C is a cysteine, A is an aliphatic amino acid, and X is a methionine, glutamine, serine, or threonine), a data base search was performed to identify CAAX box proteins that could potentially be important for the G 2 3 M transition or during mitosis. Of the hundreds of potentially farnesylated peptides that were identified from Swiss-Prot, two proteins, CENP-E and CENP-F/ mitosin, were previously associated with mitosis (19 -37) . Specifically, a role for both CENP-E and CENP-F/mitosin prior to the metaphase-anaphase transition was previously suggested (20, 21, 23, 28, 29, 36, 37) . Both CENP-E and CENP-F/mitosin are localized on kinetochores, and CENP-E is attached to the kinetochores and microtubules (19, 20, 29, 31) .
Rieder and others have clearly shown the existence of a spindle checkpoint or a kinetochore attachment checkpoint prior to metaphase progression. This checkpoint appears to monitor the interaction of chromosomes with the spindle microtubules, and chromosomes that fail to attach to the spindle appear to inhibit sister chromatid separation at least transiently (38 -41) . It was demonstrated that sister chromatid separation is defective when CENP-E function is blocked by microinjection of affinity-purified antibodies to CENP-E (23, 28, 29) . CENP-F/mitosin, which is one of the first proteins that associates with the kinetochores in prophase, is expressed only during mitosis and is rapidly degraded thereafter (34) . These findings signify the importance of functional CENP-E and CENP-F/mitosin during mitosis and make them ideal candidate proteins for FTI targets.
A detailed study was performed on CENP-E and CENP-F/ mitosin to determine whether these proteins were substrates for the enzyme FPT in vitro and in vivo and to determine whether prenylation had a role in the function of the two proteins.
EXPERIMENTAL PROCEDURES
Cell Culture and Growth Assays-The hTCLs, A549, and NCI-H460 (derived from lung carcinomas), MIA Pa Ca-2 (derived from pancreatic carcinoma), and DLD-1 (derived from colon carcinoma) were obtained from American Type Culture Collection (Manassas, VA) and maintained according to their recommendation. * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Farnesyl Transferase Inhibitors-The farnesyl transferase inhibitor SCH 66336 was described previously (16) .
Cell Lysate Preparation and Western Blot Analysis-To collect total protein, cells grown in appropriate medium were washed with PBS and scraped off of 10-cm dishes. After one more wash with PBS, the cell pellets were resuspended in a 1ϫ protease inhibitor mixture mix (Complete Tablets from Roche Molecular Biochemicals), and 1% Nonidet P-40 was added to the pellets. After a 30-min incubation on ice, the pellets were sonicated, and the insoluble cell debris was removed by centrifugation at 15,000 ϫ g for 5 min. The protein concentration was measured using the BCA protein assay from Pierce. 6 or 8% gels were used to detect CENP-E and CENP-F/mitosin from 60 g of total protein.
Proteins were transferred to polyvinylidene difluoride membranes overnight at 20 V and 4°C and probed with the specific antibodies. For CENP-F/mitosin, the mitosin antibody from Transduction Laboratories was diluted 1:1000. For CENP-E, a polyclonal antibody was synthesized by immunizing two rabbits (SYNPEP Corp., Dublin, CA). This antibody was diluted 1:1000. For actin, the ascites fluid (Ab-1 antibody; Oncogene Research Products) was diluted 1:500. Horseradish peroxidaselinked secondary antibodies were obtained from New England Biolabs.
Cell Cycle Analysis-For FACs analysis 0.5-1 ϫ 10 6 cells were grown in 10-cm tissue culture plates with or without 1 M SCH 66336. After 72 h, cells were collected from the culture medium. These were mixed with cells from the tissue culture plate after trypsinization. Cells were then washed with PBS, fixed with 70% methanol for 30 min at 4°C, and stained directly with propidium iodide solution (0.05 mg/ml propidium iodide, 0.1% Triton X-100, 0.1 mM EDTA, 0.05 mg/ml RNase A). 10,000 stained cells were analyzed by flow cytometry in a Becton Dickinson flow cytometer and analyzed using MODFIT LT (Verity Software Inc.)
Determination of FPT and GGPT-I Activity by Scintillation Proximity Assay Using Peptide Substrates-Biotinylated peptides derived from the carboxyl terminus of Ha-Ras, a mutant form of lamin B (CAIM 3 CAIL), CENP-E and CENP-F/mitosin were synthesized by SYNPEP. The sequences for the peptides are as follows: Ha-Ras, biotin-DESG-PGCMSCKCVLS; mutant lamin B, biotin-SGSGYRASNRSCAIL; CENP-E, biotin-GKDVPECKTQ; CENP-F, biotin-SKGSENCKVQ. Biotinylated peptides were used as substrates to detect the transfer of the [ 3 H]isoprenyl group from the farnesyl pyrophosphate or the geranylgeranyl pyrophosphate in the presence of purified recombinant human FPT or GGPT-I in vitro as described previously (18, 43, 44) . After a 35-min incubation, peptides were collected with streptavidin-coated beads and the incorporation of [ 3 H]isoprene was detected using the scintillation proximity assay. Ha-Ras, which is a substrate for FPT but not GGPT-I, and a mutant lamin B peptide, which is a substrate for GGPT-I but not FPT, were used as controls.
Detection of CENP-E and CENP-F/Mitosin by Immunohistochemistry-A549 cells (control (untreated), and cells treated with 1 M 66336 for 4 days) were fixed in 3.7% formaldehyde, washed three times with PBS, and treated with 0.1% Triton X-100 to permeablize cells. After three washes with PBS, they were incubated with the primary antibody for 1 h, washed three times with PBS, and subsequently incubated with a fluorescein isothiocyanate-conjugated secondary antibody. They were also stained with propidium iodide solution (0.05 mg/ml propidium iodide, 0.1% Triton X-100, 0.1 mM EDTA, 0.05 mg/ml RNase A). After five washes in PBS and one wash in water, cells were immobilized in elvanol and visualized by fluorescence microscopy (ϫ 1000).
For CENP-F/mitosin, a monoclonal antibody was obtained from Transduction Laboratories. For CENP-E, a polyclonal antibody to the peptide LRRSQQAQDTSVISEHTDPQPSNKPL, near the COOH terminus of CENP-E, was synthesized by immunizing two rabbits (SYNPEP Corp., Dublin, CA). The antibodies from the two rabbits (enzyme-linked immunosorbent assay titers 12,500 and 10,500, while titer from preimmune serum was Ͻ50) were pooled together and affinity-purified by the manufacturer. For immunohistochemistry, the affinity-purified CENP-E antibody was diluted 1:300, and the mitosin antibody was diluted 1:100. Fluorescein isothiocyanate-conjugated secondary antibodies were obtained from ICN chemicals and used according to the manufacturer's specifications. (15) , were grown in medium containing 20 M mevastatin and 10% dialyzed FBS for 2 h. The culture medium was then replaced with culture medium with 10% dialyzed FBS containing 1 M SCH 66336 (or Me 2 SO for control cells), 150 Ci/ml [ 3 H]mevalonolactone, and 20 M mevastatin to metabolically label prenylated proteins overnight. After washing twice with cold PBS, the cells were harvested in radioimmune precipitation buffer containing protease inhibitors. The primary CENP-F/mitosin antibody was added to the total protein lysate along with protein G/protein A-Sepharose beads, and the tubes with the lysate were rotated for 2 h. The beads were collected by centrifugation and washed twice before sample buffer was added. The samples were boiled in water bath and loaded on 8% SDS-polyacrylamide gel electrophoresis gels. The gels were dried on a Whatman paper after electrophoresis and viewed by autoradiography. The lysate depleted of CENP-F/mitosin was used for detection of labeled CENP-E and subsequently for K-Ras using the antibody K-Ras (F-234) from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Mevalonate Labeling of CENP-E and CENP-F/Mitosin in the Absence and Presence of SCH 66336 -pMev-DLD-1, DLD-1 cells expressing a mevalonate transporter gene
Isolation of Microtubule-associated Proteins-A549, NCI-H460, and MIA Pa Ca-2 cells were grown for 3 days without and with 1 M SCH 66336. Microtubule-associated proteins were isolated from these human tumor cell lines using the previously described method for high microtubule-associated protein (MAP) content (45) after two cycles of depolymerization-polymerization of the microtubules. The depolymerization of the microtubules was achieved by incubation on ice. This was followed by polymerization of the microtubules at 32°C in the presence of GTP, PEP, and pyruvate kinase as described previously (45) . The microtubule-associated proteins were used for Western blot analysis of CENP-E and for silver staining using the Silver XPress kit from NOVEX.
RESULTS

Data Base Search for CAAX Box
Proteins-To identify farnesylated proteins that could contribute to a G 2 3 M pause, the FINDPATTERNS algorithm was used to obtain proteins with CAAX boxes at their COOH-terminal ends from the Swiss-Prot data base. This search revealed more than 300 CAAX box peptide sequences that could potentially be prenylated. Three of these proteins, CENP-E, CENP-F, and mitosin, with CAAX boxes CKTQ, CKVQ, and CKVQ, are known to be kinetochorebinding proteins that are expressed during mitosis (28, (33) (34) (35) . All three are expressed in a cell cycle dependent fashion, are transiently associated with kinetochores/centromeres during mitosis, and regulate progression through the G 2 3 M checkpoint (19) .
A protein pileup for CENP-F and mitosin revealed that they have identical amino acid sequences, except for a stretch of 96 amino acids that is missing in mitosin. Thus, the two proteins may be products of alternatively spliced transcripts from the same gene, and since we do not distinguish between the two forms, we refer to them as CENP-F/mitosin.
The fact that CENP-E and CENP-F/mitosin have CAAX boxes and the fact that they play a role in G 2 3 M progression suggest that these proteins may be important in mediating some of the cell cycle changes induced by FTIs.
Peptides from the COOH-terminal End of CENP-E and CENP-F/Mitosin Are Substrates for FPT but Not GGPT-I-To
determine whether CENP-E and CENP-F/mitosin were substrates for FPT and GGPT-I, biotinylated peptides from the COOH-terminal ends of CENP-E and CENP-F/mitosin were synthesized. The peptides were tested as substrates for FPT and GGPT-I using 3 H-labeled farnesyl pyrophospate and 3 Hlabeled geranylgeranyl pyrophospate, respectively, as isoprene donors. A COOH-terminal Ha-Ras peptide and a mutated lamin B peptide (in which the CAAX box CAIM was changed to CAIL) were used as controls for farnesylation and geranylgeranylation, respectively. Both peptides corresponding to the COOH-terminal CAAX sequences of CENP-E and CENP-F/ mitosin were substrates for FPT (Fig. 1A) . The apparent K m of CENP-E and CENP-F/mitosin for FPT was approximately 200 nM as compared with the Ha-Ras peptide, which has a K m of approximately 550 nM. This indicates that in vitro, the COOH-terminal peptides of both CENP-E and CENP-F/mitosin had higher affinity for FPT than the synthetic Ha-Ras peptide.
Significantly, the CENP-E and CENP-F/mitosin peptides were not substrates for GGPT-I in vitro. As expected, the mutated lamin B peptide was a good substrate for GGPT-I under the same conditions, indicating that the enzyme was functional in the experiments (Fig. 1B) . These results suggested that CENP-E and CENP-F/mitosin may not be in vivo substrates for GGPT-I. This is in contrast to K-Ras and N-Ras, which were shown to be substrates for both GGPT and FPT in vitro (18) . In vivo, K-Ras and N-Ras are farnesylated proteins, but in FTItreated cells these proteins are alternatively prenylated by GGPT-I (14, 15) .
SCH 66336 Prevents the Incorporation of [ 3 H]Mevalonate into Endogenous CENP-E and CENP-F/Mitosin in a Human
Tumor Cell Line-The prenylation of CENP-E and CENP-F/ mitosin was examined in pMev-DLD-1 cells. Studying the prenylation pattern of endogenous proteins is difficult in human tumor cell lines, where incorporation of mevalonate is limited. pMev-DLD-1 is a cell line developed to increase the incorporation of mevalonate (15) . In addition, for this experiment, antibodies were required to immunoprecipitate endogenous CENP-E and CENP-F/mitosin from the pMev-DLD-1 cells. The CENP-F/mitosin antibody was commercially available.
The CENP-E antibody was generated against a peptide from the COOH-terminal region of CENP-E as described under "Experimental Procedures." Western blot analysis performed with the affinity-purified CENP-E antibody revealed a band migrating at ϳ250 kDa in HCT 116 ( Fig. 2A) and all other human tumor cell lines that were tested (data not shown) as reported earlier (23) . The antibody was shown to be specific for CENP-E because incubation with the peptide blocked immunoreactivity ( Fig. 2A) .
pMev-DLD-1 cells were grown in the presence of 3 H-labeled mevalonolactone (precursor for both the farnesyl and the geranylgeranyl pyrophosphate) and mevastatin (which prevents the synthesis of cellular mevalonate) in the presence and in the absence of the FTI. Protein lysates collected from the cells were immunoprecipitated with mitosin antibody and resolved by SDS-PAGE as shown in Fig. 2B .
3 H-Labeled mevalonate was incorporated into mitosin, indicating that it is a prenylated protein. However, the incorporation of the label from 3 H mevalonolactone was completely blocked in the presence of a farnesyl transferase inhibitor, SCH 66336 (Fig. 2B) , indicating that CENP-F/mitosin is a farnesylated protein and not subject to alternative prenylation. Western analysis confirmed that CENP-F/mitosin was not repressed in FTI-treated cells (Fig. 2C) , suggesting that the loss of signal was due to inhibition of prenylation and not due to a reduction in protein expression.
CENP-E was immunoprecipitated using the anti-CENP-E antibody from the protein lysate that had been depleted of mitosin and resolved by SDS-polyacrylamide gel electrophoresis. Like CENP-F, CENP-E was not repressed by FTI treatment (Fig. 2C) , and CENP-E also incorporated 3 H-labeled me- . CENP-F/mitosin and CENP-E that were mevalonate-labeled in p-Mev-DLD-1 cells were immunoprecipitated with their specific antibodies as described and resolved on an 8% Tris-glycine gel, and labeled K-Ras was resolved on a 14% gel. The gels were dried on a gel dryer with a Whatman paper backing and observed by autoradiography. C, Western analysis using 60 g of total protein from DLD-1 cells grown in the absence (untreated) and presence of 1 M SCH 66336 (FTI). To ensure that equal amounts of total protein were used in both lanes, CENP-E blots were probed with the actin antibody as described under "Experimental Procedures." Mitosin was probed on a separate blot. 3 H]geranylgeranyl pyrophospate (B) in vitro as described previously (18) . SPA, scintillation proximity assay.
valonate only in the absence of FTI (Fig. 2B ). To ensure that 3 H-labeled mevalonolate was incorporated in FTI-treated pMev-DLD-1, K-Ras, which is alternatively prenylated in the presence of FTIs, was immunoprecipitated from the same lysate. As expected, K-Ras was labeled in both untreated and FTI-treated cells (Fig. 2B) (15) .
These results confirm that in whole cells, both CENP-E and CENP-F/mitosin are farnesylated proteins, and it is important to note that the presence of the FTI does not lead to the alternative prenylation of either CENP-E or CENP-F/mitosin in cells.
FTIs Induce a G 2 3 M Pause in A549 Cells-The lung carcinoma cells, A549, which harbor a K-ras mutation, were shown to be sensitive to the effects of FTIs (2, 3, 46) . To evaluate the ability of SCH 66336 to alter the cell cycle distribution, flow cytometry was performed on A549 cells in the presence of SCH 66336. As observed earlier with human tumor cells lacking Ha-ras mutations, A549 cells treated with 1 M SCH 66336 pause in the G 2 3 M phase (Fig. 3 Immunohistochemistry was performed to determine the precise stage of the mitotic pause. Cells were stained with propidium iodide to identify mitotic cells. Although initially, 10,000 cells were grown on each coverslip, the doubling time of the cells was different in the absence and in the presence of FTI. Thus, the mitotic index was not compared. Instead, mitotic cells were counted randomly from 50 -60 microscopic fields (each showing a total of 10 -50 cells), and the mitotic cells were grouped depending on their mitotic stage (namely prophase, prometaphase, metaphase, anaphase, or telophase, depending on the arrangement of cellular DNA) (Fig. 4) . The comparison of the number of cells in the different mitotic stages revealed that more cells were in prophase and prometaphase upon FTI treatment, and cells in anaphase or telophase were rarely observed.
CENP-E and CENP-F/Mitosin Remain Associated with the Centromeres in the Presence of FTI-Immunohistochemistry
was performed to determine any changes in the localization of CENP-F/mitosin and CENP-E in cells treated with 1 M SCH 66336. From prometaphase to early anaphase, CENP-F/mitosin was clearly associated with the kinetochores, whereas in late anaphase after sister chromatid separation it was expressed in the midbody. These observations are similar to the expression studies reported earlier (34) . The localization of CENP-F/mitosin to the kinetochores during prometaphase was not affected by FTI treatment for 4 days. The staining of kinetochores themselves in FTI-treated cells, however, appeared scattered in the prometaphase rosettes in contrast to untreated A549 cells that are not exposed to FTI (Fig. 5, A and B premitotic cells where it is perinuclear. Like CENP-F, CENP-E is also localized to the kinetochores from prophase to early metaphase; however, in anaphase it associates with the mitotic spindle. Association with both the kinetochores and the microtubules was clearly seen with the CENP-E antibody in untreated A549 cells. The treatment of A549 cells with SCH 66336 did not affect the localization of the CENP-E to the kinetochores in prometaphase (Fig. 5, C and D) . Thus, farnesylation does not appear to be necessary for the localization of CENP-E to the kinetochores themselves.
FTIs Alter the Microtubule Association of CENP-E-To determine whether farnesylation of CENP-E was important for the association of CENP-E with the microtubules, this association was examined in the presence and absence of 1 M SCH 66336. MAPs isolated from the lung carcinoma, A549, were purified from FTI-treated and control cells by two rounds of depolymerization and polymerization as described under "Experimental Procedures." The MAPs were resolved by gel electrophoresis and Western blotted with the CENP-E antibody. The same amount of MAPs from untreated and FTI-treated cells that were used for Western analysis (Fig. 6A) were also visualized by silver staining (Fig. 6B) . Most microtubule-associated proteins were present in equal amounts in both untreated and FTI-treated cells except for CENP-E. To show that the drastic reduction of CENP-E in the MAP preparation of FTI-treated cells was not due to the lack of expression of CENP-E in FTI-treated cells, silver staining was also performed on total protein from untreated and FTI-treated A549 cells. Our results clearly indicate that blocking the farnesylation of CENP-E affects the association of CENP-E to the microtubules. MAPs were also purified from NCI-H460 and MIA Pa Ca-2 cells in the absence and presence of 1 M SCH 66336, and Western analysis of CENP-E from these MAP preparations also showed a significant reduction of microtubule-associated CENP-E (Fig. 6C ).
DISCUSSION
Studies using farnesyl transferase inhibitors have clearly shown that tumor cells expressing an activated Ha-Ras are sensitive to their growth-inhibitory effects because Ha-Ras is not alternatively prenylated and its membrane association is blocked in the presence of FTI. Thus, FTIs block the proliferation signals that emanate from activated Ha-Ras. However, the sensitivity of other human tumor cell lines is less easily explained, since other Ras forms (K and N) are alternatively prenylated in FTI-treated cells. Previous studies have shown that FTIs induce a G 2 3 M pause in cells lacking ras mutations or cells harboring K-ras mutations, indicating that in these cells, FTIs elicit a distinct biological effect from that observed in Ha-ras-transformed cells (46) . 2 Taken together, these data suggest that farnesylated proteins, other than Ras, are important in mediating the sensitivity of some cells to FTIs.
CENP-E and CENP-F/mitosin were identified in the SwissProt data base with an algorithm that detects the CAAX farnesylation motif. These centromere-associated proteins are regulated during mitosis and may contribute to the mitotic checkpoint (19) . Because these proteins are important for the G 2 3 M transition and they were predicted to be substrates for FPT, they were studied in detail to determine whether they could mediate some of the biological effects of the FTIs.
Prenyl Analysis of CENP-E and CENP-F-
The results presented here clearly demonstrate that peptides derived from CENP-E and CENP-F are substrates for FPT but not GGPT-I in vitro and that they incorporate radiolabeled mevalonate in cells. Mevalonate incorporation into these proteins can be completely blocked in the presence of the FTI, SCH 66336, suggesting that neither protein is alternatively prenylated (geranylgeranylated) in cells treated with FTIs. Farnesylation of CENP-E and CENP-F/mitosin has not been previously described, and the role of farnesylation in the localization and biological activity of these proteins has not been characterized. Classically, the farnesylation of proteins was viewed as important for localization to cellular membranes. This has been explored in detail for the trafficking and plasma membrane localization of the Ras family of proteins (47) (48) (49) (50) (51) . Recently, several lines of evidence have shown that, under certain conditions, K-Ras becomes associated with microtubules in a prenylation dependent fashion (52) . These results and the observation that a number of nuclear proteins such as lamin B and PTPCAAX1 are farnesylated suggests that this posttranslational modification may be important for interacting with other cellular structures.
Farnesylation and the Function of CENP-F-The kinetochore is a trilamellar multifuctional structure associated with centromeres and is involved in microtubule attachment and chromosome segregation during mitosis (42, 53) . However, the normal progression of mitosis is subject to checkpoint controls. Metaphase progression requires kinetochore attachment to the spindle and can be delayed by the presence of just one unattached kinetochore (39, 41) . CENP-F/mitosin is a centromeric protein localized to the kinetochore, specifically the outer kinetochore plate, during prometaphase (34) . It is one of the first transient proteins that attaches to the kinetochores when the centromere begins its transformation from an amorphous electron dense mass to highly organized trilamellar structure (34) . The immunohistochemical data presented here revealed that localization of CENP-F to the centromeres is not affected in the presence of the FTI. This observation suggests that farnesylation is not required to mediate kinetochore interaction with CENP-F. The association of CENP-F to the kinetochores may facilitate interaction with other G 2 3 M proteins. However, we have not been able to elucidate a specific role for farnesylation in the biological function of CENP-F.
Farnesylation and the Function of CENP-E-CENP-E is a
centromere-associated kinesin motor protein that is localized to the outer kinetochore plate during prophase and has two microtubule binding domains: one at the NH 2 terminus and the other at the COOH terminus (31) . Evidence exists that CENP-E is required for establishing the kinetochore-microtubule connection that is necessary for normal segregation of the sister chromatids during mitosis (31) .
Normally during prophase, chromosomes are scattered before the microtubule-kinetochore connections are made. The bipolar attachment of microtubules to the kinetochores is necessary for chromosome alignment and equal chromosome distribution at the end of mitosis (53) . Our observations that the cells accumulate in prometaphase and that there are fewer cells in the later phases of mitosis (metaphase and anaphase) following FTI treatment may reflect disregulation of kinetochore-microtubules interaction prior to alignment of chromosomes during metaphase.
Schaar et al. (29) reported that microinjection of antibodies to 360 amino acids in the COOH of CENP-E prevented the localization of CENP-E to the kinetochores in the U2OS cells, and in these cells the chromosomes failed to align along the metaphase plate during mitosis. The results strongly suggest that CENP-E is required for coupling chromosomes through their kinetochores to the depolymerizing microtubules and that the specific inactivation of CENP-E was sufficient to destabilize chromosome-microtubule interactions during mitosis (29) . Our results show that the inhibition of farnesylation interferes with the CENP-E-microtubule association. In the presence of FTI, chromosome alignment to the metaphase plate is delayed, which coincides with the increase in the G 2 3 M population observed in many cell types in response to FTI treatment. The delay in chromosome alignment in FTI-treated cells may be similar to that seen with the microinjection of the COOHterminal CENP-E antibody in U2OS cells (29) . Taken together, these studies imply that the dissociation of CENP-E from either the kinetochores or the microtubules is sufficient to delay mitotic progress.
FTIs, CENP-E, CENP-F, and the G 2 3 M Checkpoint-The results presented here show that two centromeric proteins, CENP-E and CENP-F, are substrates for the enzyme farnesyl protein transferase and are not alternatively prenylated (geranylgeranylated) in the presence of the FTIs. Both CENP-E and CENP-F are associated with the centromeres in the presence of FTIs. Blocking farnesylation of CENP-E affects its association with microtubules, suggesting that a functional association of CENP-E with the microtubules requires farnesylation.
In FTI-treated cells, the accumulation of cells prior to metaphase and the activation of a G 2 3 M checkpoint due to the disruption of microtubule-kinetochore interactions can be explained by the inhibition of CENP-E function alone. This does not exclude the possibility that other nuclear farnesylated proteins including CENP-F could enhance this effect or mediate a similar effect. Results presented here suggest that FTIs have biochemical and biological effects on nuclear proteins associated with centromeres/kinetochores and that these effects may contribute to the mechanism of action of FTIs.
An important question is whether the biological effects described in this work contribute to the chemotherapeutic effects of the FTIs and to their observed synergy with the microtubuletargeting taxanes (1) . 3 Our studies are consistent with the observations that FTIs induce a G 2 3 M pause in sensitive human tumor cells and activate the G 2 3 M checkpoint through altered microtubule-kinetochore interactions. However, the cellular fate of a hTCL after the activation of the G 2 3 M checkpoint may differ, depending on other genetic factors of the hTCL.
